Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01410942 · ClinicalTrials.gov registry record · Phase 2

Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy

A Phase 2 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.

Active
Registry status
Phase 2
Development phase
175
Enrollment target
1
Study location

NCT01410942: Active Phase 2 study of Prostate Cancer, sponsored by M.D. Anderson Cancer Center.

NCT01410942 is a Phase 2 study of Prostate Cancer that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 175 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01410942, a Phase 2 study of Prostate Cancer, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
175 participants
Enrollment target
1
Study location

Study Summary

The goal of this clinical research study is to learn about the effect of different combinations of exercise, supportive counseling, and methylphenidate/placebo for the treatment of fatigue in patients with prostate cancer. The safety of this treatment combination will also be studied. Methylphenidate is a stimulant designed to increase the activity of the central nervous system. A placebo is not a drug. It looks like the study drug but is not designed to treat any symptom, disease or illness. It is designed to be compared with a study drug to learn if the study drug has any real effect. The exercise in this study is designed to help improve your physical fitness and energy levels. Supportive counseling is designed to help to control symptoms, fatigue, anxiety, depression, pain, and/or sleep disorders.

Conditions Studied

Prostate Cancer

Interventions

  • OTHER Placebo
  • DRUG Methylphenidate
  • BEHAVIORAL Counseling Sessions
  • OTHER Sham Exercise
  • OTHER Standardized Exercise Intervention Program

Study Locations (1)

Texas

  • University of Texas MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 175 participants
Start Date 2012-02-08
Est. Completion 2026-09-30
Phase Phase 2

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01410942

The ClinicalTrials.gov registry entry for NCT01410942 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 175 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (71% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 5 interventions - of which Placebo is the first listed.

NCT01410942 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT01410942 about?

NCT01410942 is a clinical study titled "Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy". The goal of this clinical research study is to learn about the effect of different combinations of exercise, supportive counseling, and methylphenidate/placebo for the treatment of fatigue in patients with prostate cancer. The safety of this treatment combination will also be studied. Methylphenida...

What is the current status of trial NCT01410942?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2012-02-08. Estimated completion is 2026-09-30.

What conditions does trial NCT01410942 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT01410942?

The interventions under investigation include: Placebo (OTHER), Methylphenidate (DRUG), Counseling Sessions (BEHAVIORAL), Sham Exercise (OTHER), Standardized Exercise Intervention Program (OTHER).

Who is sponsoring clinical trial NCT01410942?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01410942 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Texas

All trials with a study site in Texas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.